Literature DB >> 18497498

Spontaneous regression of an asymptomatic meningioma associated with discontinuation of progesterone agonist administration.

Jun Shimizu1, Masayoshi Matsumoto, Etsuo Yamazaki, Masaharu Yasue.   

Abstract

An 80-year-old male visited the hospital as an outpatient with a head injury sustained in a traffic accident. Brain computed tomography incidentally revealed a left frontal lobe tumor measuring 5 cm in a diameter. The patient had a history of taking chlormadinone acetate (a progesterone agonist) prescribed several years previously as treatment for benign prostatic hypertrophy. The tumor was seen as an isointense lesion on T(1)-weighted magnetic resonance (MR) images with enhancement by gadolinium, and as a heterogeneously hyperintense mass on T(2)-weighted MR images. The tentative diagnosis was left frontal meningioma attached to the sphenoid ridge or sphenoid plane. The patient was managed conservatively because of his advanced age and no symptoms or progression were observed during a 9-month follow-up period. The medication for benign prostatic hypertrophy was changed from chlormadinone acetate to naftopidil (an alpha-2-blocker) about 9 months after his first presentation. The patient presented again 2 years later complaining of dizziness. Computed tomography and MR imaging performed at this time revealed remarkable regression of the tumor. The signal intensity change with regression of the tumor on T(2)-weighted images was observed as a hypointense lesion. Thus, we wish to emphasize that treatment of meningiomas, especially those diagnosed incidentally, must be based on a thorough consideration of any history of hormonal therapy with prostate disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18497498     DOI: 10.2176/nmc.48.227

Source DB:  PubMed          Journal:  Neurol Med Chir (Tokyo)        ISSN: 0470-8105            Impact factor:   1.742


  8 in total

1.  Abrupt regression of a meningioma after discontinuation of cyproterone treatment.

Authors:  A M G Gonçalves; P Page; V Domigo; J-F Méder; C Oppenheim
Journal:  AJNR Am J Neuroradiol       Date:  2010-01-06       Impact factor: 3.825

2.  Spontaneous regression together with increased calcification of incidental meningioma.

Authors:  Kengo Hirota; Toshiyuki Fujita; Hiroyuki Akagawa; Hideaki Onda; Hidetoshi Kasuya
Journal:  Surg Neurol Int       Date:  2014-05-21

3.  Progression of intracranial meningioma during luteinizing hormone-releasing hormone agonist treatment for prostate cancer: case report.

Authors:  Takeo Anda; Masaru Honda; Tokuhiro Ishihara; Toshiaki Kamei
Journal:  Neurol Med Chir (Tokyo)       Date:  2013-11-08       Impact factor: 1.742

4.  Spontaneous Regression of an Incidental Spinal Meningioma.

Authors:  Ali Yilmaz; Zahir Kizilay; Ahmet Sair; Mucahit Avcil; Ayca Ozkul
Journal:  Open Access Maced J Med Sci       Date:  2015-12-21

5.  Regression of Intracranial Meningioma during Treatment with α1-Adrenoceptor Blocker.

Authors:  Einar August Hoegestoel; Jon Berg-Johnsen
Journal:  J Neurol Surg Rep       Date:  2016-03

6.  Possible Abscopal Effect Observed in Frontal Meningioma After Localized IMRT on Posterior Meningioma Resection Cavity Without Adjuvant Immunotherapy.

Authors:  Danielle Golub; Kevin Kwan; Jonathan P S Knisely; Michael Schulder
Journal:  Front Oncol       Date:  2019-10-18       Impact factor: 6.244

7.  Spontaneous regression of a posterior fossa meningioma: A case report.

Authors:  Maya Takada; Kiyoyuki Yanaka; Kazuhiro Nakamura; Ken Akimoto; Hayato Takeda; Eiichi Ishikawa
Journal:  Surg Neurol Int       Date:  2022-08-05

8.  Risk of intracranial meningioma with three potent progestogens: A population-based case-control study.

Authors:  Léa Hoisnard; Moussa Laanani; Thibault Passeri; Lise Duranteau; Joël Coste; Mahmoud Zureik; Sébastien Froelich; Alain Weill
Journal:  Eur J Neurol       Date:  2022-06-20       Impact factor: 6.288

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.